A. Stähle

Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆

U WAGNER, Andreas duBois, J. Pfisterer et al. · Gynecologic Oncology · 2006 · 89 citations

Medicine, Oncology, Pharmacology +17

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

Felix Hilpert, A. Stähle, O. Tomé et al. · Supportive Care in Cancer · 2005 · 70 citations

Medicine, Oncology, Pharmacology +13

Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut)

Andreas du Bois, Jacobus Pfisterer, Nicole Burchardi et al. · Gynecologic Oncology · 2007 · 60 citations

Medicine, Gynecology, Oncology +15

Gemcitabine/carboplatin (GC) vs. carboplatin (C) in platinum sensitive recurrent ovarian cancer (OVCA). Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG

Jacobus Pfisterer, Marie Plante, Ignace Vergote et al. · Journal of Clinical Oncology · 2004 · 60 citations

Medicine, Gynecology, Oncology +16

Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): A prospective, randomized multicentre phase III study of the AGO breast cancer study group

Hans-Joachim Lueck, Gϋnter von Minckwitz, Andreas du Bois et al. · Journal of Clinical Oncology · 2006 · 25 citations

Medicine, Oncology, Pharmacology +17